Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study

Eitemau Tebyg

• Postinjection delirium/sedation syndrome in patients with schizophrenia receiving olanzapine long-acting injection: results from a large observational study
  gan: Meyers, Kristin J., et al.
  Cyhoeddwyd: (2017)
• Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study
  gan: McDonnell, David P., et al.
  Cyhoeddwyd: (2014)
• Within‐drug benefit‐risk evaluation of olanzapine long‐acting injection at one and two years of treatment
  gan: Detke, Holland C., et al.
  Cyhoeddwyd: (2014)
• Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
  gan: Ascher-Svanum, Haya, et al.
  Cyhoeddwyd: (2014)
• A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection
  gan: Atkins, Susan, et al.
  Cyhoeddwyd: (2014)